Oddity Tech Ltd., is a consumer-tech company globally. The company is headquartered in Tel Aviv-Jaffa, Israel.
| Revenue (TTM) | $679.09M |
| Gross Profit (TTM) | $475.42M |
| EBITDA | $5.14M |
| Operating Margin | -0.70% |
| Return on Equity | 5.10% |
| Return on Assets | -0.48% |
| Revenue/Share (TTM) | $12.41 |
| Book Value | $5.10 |
| Price-to-Book | 3.38 |
| Price-to-Sales (TTM) | 1.52 |
| EV/Revenue | 1.75 |
| EV/EBITDA | 168.44 |
| Quarterly Earnings Growth (YoY) | -69.60% |
| Quarterly Revenue Growth (YoY) | -25.10% |
| Shares Outstanding | $34.58M |
| Float | $29.52M |
| % Insiders | 6.85% |
| % Institutions | 112.17% |
Volatility is currently contracting
Oddity Tech (ODD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
KMX, ACIC, ONC, ODD and WES have been added to the Zacks Rank #1 (Strong Buy) List on October 15, 2026.
NANJING, China, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that opamtistomig (LBL-024), the Company's proprietary PD‑L1/4‑1BB bispecific antibody, has been granted Orphan Drug Designation (ODD) by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of extrapulmonary neuroendocrine carcinoma (EP-NEC). This is the third Orphan Drug Designation for opamtistomig, following designations in the U.S. Food and Drug Administration (FDA) and the European Commission (EC), marking a further expansion of its global regulatory recognition into a strategically important Asian market.
Oddity Tech (ODD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
ODD's turnaround could benefit from improving acquisition costs, even if profitability takes longer to recover than revenue. SpoiledChild is a nice, growing revenue base. And METHODIQ and Labs offer longer-term opportunities beyond IL MAKIAGE's potential recovery. ODD also has convertible bonds trading at a discount and a 0% coupon. This is essentially cheap debt that gives ODD flexibility and an interesting value lever.
ODDITY (NASDAQ:ODD) shares jumped 14% on Thursday after the company posted second-quarter results that topped Wall Street estimates and issued a stronger-than-expected full-year profit outlook. The consumer tech company reported revenue of $181 million for the quarter, beating estimates of $178 million but down 25% from a year earlier.
ODDITY Tech NASDAQ: ODD reported second-quarter 2026 net revenue of $181 million, down 25% from a year earlier, as its IL MAKIAGE brand continued to face higher customer-acquisition costs tied to an advertising-account dislocation with its largest ad partner.
Oddity Tech (ODD) came out with quarterly earnings of $0.2 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.92 per share a year ago.
Second quarter net revenue of $181 million, down approximately 25% year-over-year Second quarter adjusted EBITDA of $13 million Second quarter net income of $13 million and second quarter adjusted net income of $11 million Strong liquidity position including cash, cash equivalents and investments of $561 million, and aggregate credit facilities of $350 million which remain undrawn NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- ODDITY Tech Ltd.
NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- ODDITY Tech Ltd. (NASDAQ: ODD) today announced that it will release its second quarter 2026 financial results before the market open on Wednesday, September 9, 2026, to be followed by a conference call at 8:30 a.m.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ODD and any ticker you trade — then tracks every position and per-strategy win rate.
